Therefore, the first gene therapy to market will be the one with the most comprehensive, long-term data. Nonetheless, BioMarin would benefit from the ...
https://www.google.com/url?rct=j&sa=t&url=https://www.thepharmaletter.com/article/biomarin-s-roctavian-could-change-the-landscape-in-severe-hemophilia-a-analyst-says&ct=ga&cd=CAIyGmEyNDJjNTAxZWU3OTQyNzI6Y29tOmVuOlVT&usg=AFQjCNHPnT9oNnwXfAQtWRoqES8Eu44jZA
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.